Groundbreaking cancer drug enters first human trials
NCT ID NCT03036228
Summary
This completed Phase 1 trial tested the safety of a new oral drug called Karonudib in 63 adults with advanced solid tumors. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers also looked for early signs that the drug might help control cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Stockholm, Sweden
-
Sahlgrenska University Hospital
Gothenburg, Sweden
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.